Medical Information
India
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for India Healthcare Professionals. Would you like to proceed?

I am a healthcare professional registered to practice in IndiaYes, I am a healthcare professional
SelectI am a healthcare professional registered to practice in IndiaYes, I am a healthcare professional
I am a patient/caregiver residing in IndiaNo, go back to the patient portal
SelectI am a patient/caregiver residing in IndiaNo, go back to the patient portal
Non-India residents click here.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.
Poster
Bhambri R, Colavecchia C, Bruno M, Chen Y, Alvir J, Roy A, Kemner J, Crowley A, Benjumea D, Gilstrap L April 2, 2022 ACC 2022 Transthyretin Amyloidosis (ATTR)

Characteristics of patients with wild-type transthyretin cardiac amyloidosis prescribed tafamidis - a real-world descriptive analysis using electronic health records

View Presentation
Poster
Sperry BW, Hanna MA, Maurer MS, Nativi-Nicolau J, Floden L, Stewart M, Wyrwich K, Barsdorf A, Kapadia H, Spertus JA April 2, 2022 ACC 2022 Transthyretin Amyloidosis (ATTR)

Health status in patients with ATTR cardiac amyloidosis receiving tafamidis: responder analysis from ATTR-ACT

View Presentation
Poster
Elliott P, Gundapaneni B, Sultan MB, Ines M, Garcia-Pavia P May 21, 2022 HFA 2022 Transthyretin Amyloidosis (ATTR)

Improved Survival With ~5 Years of Continuous Tafamidis Treatment Among Patients With NYHA Class III Transthyretin Amyloid Cardiomyopathy

View Presentation
Oral Presentation
Garcia-Pavia P, Piriou N, Barriales-Villa R, Cappelli F, Lairez O, Munteanu C, Keohane D, Mallaina P May 21, 2022 HFA 2022 Transthyretin Amyloidosis (ATTR)

Prevalence and characteristics of transthyretin amyloid cardiomyopathy in patients with left ventricular hypertrophy in the TTRACK study: An interim analysis

View Presentation
Poster
Witteles R, Sultan MB, Gundapaneni B, Garcia-Pavia P August 26, 2022 ESC 2022 Transthyretin Amyloidosis (ATTR)

Atrial Fibrillation as a Prognostic Factor for All-Cause Mortality in Patients With Transthyretin Amyloid Cardiomyopathy

View Presentation
Poster
Moody AT, Tess DA, Li Z, Bulawa C, Fleming J, Maurer TS August 26, 2022 ESC 2022 Transthyretin Amyloidosis (ATTR)

Relationship of Tafamidis Binding-Site Occupancy, Transthyretin Stabilization, and Disease Modification in Tafamidis-Treated Patients With Transthyretin Amyloid Cardiomyopathy

View Presentation
Poster
Gonzalez-Moreno J, Dispenzieri A, Grogan M, Coelho T, Tournev I, Waddington-Cruz M, Wixner J, Diemberger I, Garcia Pavia P, Chapman D, Glass O, Amass L September 5, 2022 ISA 2022 Transthyretin Amyloidosis (ATTR)

A Descriptive Analysis of Patients With ATTR Amyloidosis and a Mixed Phenotype From the Transthyretin Amyloidosis Outcomes Survey (THAOS)

View Presentation
Oral Presentation
Witteles R, Sultan MB, Gundapaneni B, Garcia-Pavia P September 5, 2022 ISA 2022 Transthyretin Amyloidosis (ATTR)

Atrial fibrillation as a prognostic factor for all-cause mortality in patients with transthyretin amyloid cardiomyopathy

View Presentation
Poster
Waddington Cruz M, Planté-Bordeneuve V, Inamo J, Kristen A, Chapman D, Glass O, Amass L September 5, 2022 ISA 2022 Transthyretin Amyloidosis (ATTR)

Characteristics of Patients With ATTR Amyloidosis and the Ile107Val Mutation: Insights From the Transthyretin Amyloidosis Outcomes Survey (THAOS)

View Presentation
Poster
Diemberger I, Lino Cirami C, Luigetti M, Dispenzieri A, Grogan M, Chapman D, Glass O, Amass L September 5, 2022 ISA 2022 Transthyretin Amyloidosis (ATTR)

Characteristics of Patients With ATTR Amyloidosis and the Ile68Leu Mutation: Insights From the Transthyretin Amyloidosis Outcomes Survey (THAOS)

View Presentation